PCM
KNSA icon

Penn Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Penn Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6M Buy
368,114
+66,121
+22% +$3.43M 1.49% 16
2026
Q1 		$14.6M Buy
+301,993
New +$13.4M 1.13% 47

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Penn Capital Management's KNSA Position: Q2 2026 in Review

Penn Capital Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 22% in Q2 2026, buying an estimated $3.43M and bringing the position to 368,114 shares worth $23.6M. The position accounts for 1.49% of the portfolio, ranked #16.

Penn Capital Management first reported a position in KNSA in Q1 2026 and has held it in 2 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Penn Capital Management held 368,114 shares of Kiniksa Pharmaceuticals worth $23.6M as of Q2 2026.
  • Penn Capital Management bought 66,121 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $3.43M.
  • Kiniksa Pharmaceuticals made up 1.49% of Penn Capital Management's portfolio in Q2 2026, its #16 holding.
  • Penn Capital Management first reported a position in Kiniksa Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.